ADP-399

N/A

Report date: 2025/01/26 15:51:04

Base Information

Drug NameADP-399
Drug Alias Namesecond-generation adiponectin agonist (Allysta Pharmaceuticals/Temple University)ADP-399
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionAdiponectin receptors agonists
TargetsAdiponectin receptors
Therapy Area/IndicationsXerophthalmiaLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAllysta Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAllysta Pharmaceuticals IncTemple University
Inactive CompaniesN/A
Active IndicationsXerophthalmiaLiver CirrhosisMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsBreast NeoplasmsLeukemia, Myelogenous, Chronic

Other Information

ATC CodeN/A
Related LinksN/A